The patient-led Global Myeloma Action Network (GMAN) recently designated March 30 as International Myeloma Action Day to raise awareness of multiple myeloma, advocate for early detection and…
The first-ever Multiple Myeloma Research Foundation (MMRF) Patient Summit was held March 25 in Denver to help patients and caregivers learn more about…
Antibody-drug conjugates (ADCs), a class of drugs in which a cancer-targeting therapy is attached to a specific monoclonal antibody without harming healthy cells, continue to…
By activating the immune system, the experimental drug LCL161 has the potential to fight myeloma in both mice and humans, according to a new study by…
The cancer charity Myeloma UK has launched a Phase 1 clinical trial testing Reolysin (pelareorep), a modulator of the immune system and cytotoxic agent, in myeloma…
Don Wright, who recently finished his 100th marathon while on active treatment for multiple myeloma, will continue running, but now with the support of the…
Multiple myeloma patients undergoing autologous stem cell transplants (ASCT) may strongly benefit from SELLAS‘ WT-1 cancer vaccine, galinpepimut-S, according to recent data from a…
GlycoMimetics will present preclinical research at the American Association for Cancer Research (AACR) Annual Meeting 2017, demonstrating the potential of two drug candidates,…
Celyad is ready to enroll patients in its Phase 1 THINK trial in Rosewell Park, N.Y. and the University of Pittsburgh Medical Center in Pennsylvania after gaining…
Patients with relapsed or refractory multiple myeloma who receive a combination of Kyprolis (carfilzomib) and dexamethasone have significantly better survival rates than those receiving Velcade (bortezomib) plus…